Duchenne Muscular Dystrophy (DMD) is a rare hereditary disease that affects the muscles and the connective tissue of the body. This condition is usually identified through skin tests and in more severe cases, it can be detected through MRI. The symptoms include drooping eyelids, decreased muscle bulk, weak pulse, and slow heart rate. The cause of this disease is not yet known but it is believed to be due to genetic differences, abnormalities in the nervous system, and infection.
Market Dynamics
High pervasiveness of DMD is relied upon to move development of the Duchenne muscular dystrophy (DMD) treatment market. For example, as per the investigation, 'Worldwide the study of disease transmission of Duchenne muscular dystrophy: a refreshed methodical audit and meta-examination's distributed in June 2020, in BMC, the pooled worldwide commonness of DMD was 7.1 cases per 100,000 guys and 2.8 cases per 100,000 in everyone, while the pooled worldwide birth pervasiveness of DMD was 19.8 per 100,000 live male births.
Research and development of new treatments for DMD treatment is relied upon to offer rewarding development openings for major parts in the Duchenne muscular dystrophy (DMD) treatment market. For example, in January 2021, Pfizer, Inc. declared that the main kid was dosed in a Phase 3 preliminary that assessed the organization's quality treatment, PF-06939926, in treating Duchenne muscular dystrophy. Also, in January 2021, Sarepta Therapeutics, Inc. declared top-line results from Part 1 of Study SRP-9001-102 to assess the security, viability and decency of a solitary portion of SRP-9001 for the treatment of DMD.
In addition, appropriation of association systems is additionally expected to offer rewarding development openings for major parts in the market. For example, in January 2021, Capricor Therapeutics, a clinical-stage biotechnology organization, collaborated with Lonza Group for the advancement of CAP-1002, its clinical resource utilizing allogeneic cardiosphere-determined cells innovation for the treatment of Duchenne muscular dystrophy.
Competitive Analysis
Major players operating in Duchenne muscular dystrophy (DMD) treatment market include, SUMMIT Therapeutics Plc., Sarepta Therapeutics, Inc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Italfarmaco Group, Sarepta Therapeutics, Pfizer Inc., Pharmacia & Upjohn LLC, and others.
Major players operating in Duchenne muscular dystrophy (DMD) treatment are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2020, The Italfarmaco Group reported that The U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to Givinostat, its proprietary histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy.
No comments:
Post a Comment